StockData
Braveheart Bio, Inc. logo

Braveheart Bio, Inc. (BRVE) stock

BRVENasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 10, 2026
$18.78−0.71 (-3.64%)

Close on Nov 17, 2026Market cap $1.69BP/E –Yield –

Braveheart Bio operating margin

Operating margin is operating income as a percentage of revenue.

No operating margin figures for Braveheart Bio

Braveheart Bio has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.

More Braveheart Bio figures

See a number that looks wrong?